 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Celltrion Group has initiated a process to seek shareholder opinions regarding a "second-stage merger" between Celltrion and Celltrion Pharmaceutical, following the merger with Celltrion Healthcare.
On the 31st, Celltrion Group announced the establishment of a "Phase 1 Special Committee for Merger Consideration," composed solely of outside directors, to evaluate the feasibility of a merger between Celltrion and Celltrion Pharmaceutical. As part of this process, the group is conducting a shareholder survey related to the potential merger.
After completing the merger with Celltrion Healthcare earlier this year, Celltrion has been exploring the possibility of merging with Celltrion Pharmaceutical from various angles. The company explained that it recognized the need for an independent and objective evaluation through the special committee. Independent special committees, composed exclusively of outside directors, have been established at both Celltrion and Celltrion Pharmaceutical. These committees will conduct comprehensive evaluations, both internally and externally, to assess the current feasibility of the merger between the two companies.
Previously, Celltrion Group Chairman Seo Jung-jin expressed his intention to pursue a three-way merger, including Celltrion Pharmaceutical, within this year, following the merger of the two companies.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
